Analysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $50.25

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $50.25.

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. HC Wainwright started coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 price target for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday, October 8th. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Insider Activity

In related news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of TG Therapeutics by 1,809.9% in the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after purchasing an additional 1,149,526 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in TG Therapeutics in the 1st quarter valued at approximately $30,545,000. Nuveen LLC bought a new position in TG Therapeutics in the 1st quarter worth approximately $29,442,000. Woodline Partners LP bought a new position in TG Therapeutics in the 1st quarter worth approximately $21,021,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of TG Therapeutics by 1,221.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock worth $15,191,000 after buying an additional 390,137 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Trading Down 0.3%

NASDAQ:TGTX opened at $31.01 on Thursday. The company has a market capitalization of $4.92 billion, a P/E ratio of 83.81 and a beta of 1.95. The stock’s 50 day moving average price is $33.95 and its 200 day moving average price is $34.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. During the same period in the previous year, the company earned $0.02 earnings per share. The company’s revenue was up 92.7% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.